Why Definium Therapeutics (DFTX) Stock Is Up 52% Today
22 Jun 2026 · 14:10 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
Definium Therapeutics stock surged as much as ~52% after its Phase 3 Emerge trial of DT120 met its primary endpoint for major depressive disorder, showing significant improvement on the depression scale.
Why it matters
The surge in Definium Therapeutics' stock is driven by positive trial results for a drug unrelated to cryptocurrencies. The low credibility score of the source and the minimal connection to crypto markets suggest that any potential impact on Bitcoin or altcoins will be negligible. Traders in the crypto space are likely to remain focused on more relevant market news.
Expected impact
The news about Definium Therapeutics' stock surge is unlikely to have a significant impact on cryptocurrency markets. The stock movement is primarily related to the pharmaceutical sector and does not directly correlate with crypto assets like Bitcoin or altcoins.